Legally Prescribed Human Growth Hormone

Omnitrope® in Italian Adults: Safety and Efficacy for Growth Hormone Deficiency

Reading Time: 4 minutes [1054 words]

A recent report highlights interim findings in assessing the safety and effectiveness of Omnitrope® in adults aged 30 years or above lacking growth hormone. The "Italian Interim Snapshot" report aims to understand the ongoing safety and effectiveness of Omnitrope®, a recombinant growth hormone identical to Genotropin®, among Italian adults participating in the PATRO Adults study suffering from growth hormone deficiency (GHD).


The PATRO Adults study is a long-term observational non-interventional international post-marketing research project in many European nations. The primary objective is to understand long-term safety, while the secondary objective is to focus on the effectiveness of Omnitrope®. The study evaluated the drug's effectiveness using measures like bone mineral density, serum insulin-like growth factor-1 levels, lipid levels, and body composition. This report presents findings from the study's Italian participants.


The study involved 67 adult patients with an average age of around 50 years, and 61% of them were males. These patients were treated with Omnitrope® over an average period of about 45.4 months, although the duration of treatment for some individuals varied by around 24.3 months. Approximately 55% of the patients noticed adverse effects during the treatment, including problems like abdominal distension, joint pain, decreased sensation, and muscle pain. To be specific, 4.5% of the subjects had adverse reactions directly associated with the drug. However, 14 patients reported adverse events, none of which were directly linked to Omnitrope®. When comparing the effectiveness of Omnitrope® with other similar medications, it was found to be equally effective. 

Overall, while a significant portion of patients experienced adverse events during treatment, Omnitrope® demonstrated comparable effectiveness to other treatments without any direct attribution to adverse events among the patients.


This research confirms that Omnitrope® is effective and safe for Italian adults suffering from growth hormone deficiency (GHD). Given the small number of participants, these findings must be validated through the entire PATRO Adults study conducted globally. It also needs to be noted here that the treatment's effectiveness varies from individual to individual and is not a magical cure or a secret to eternal life.


When the pituitary gland in adults does not produce enough growth hormone (GH), they develop a medical condition called adult-onset growth hormone deficiency (GHD). The condition is characterized by abnormal body composition, substrate metabolism, and physical and psychological functioning. Adult-onset GHD leads to problems like increased body fat, especially in the abdomen. The condition makes it difficult to control their body weight and decreases muscle mass, resulting in minimized muscle strength and exercise capacity. It also affects the mental well-being of the person, leading to higher anxiety levels and depression that impact their overall quality of life. Adult-onset GHD occurs due to hypothalamic-pituitary disease, head injuries, surgeries, and radiation treatments received for brain and pituitary tumors.

The treatment of GHD in adults is recommended with a replacement therapy that involves the use of recombinant human GH (rhGH) or synthesized human growth hormone. The dosage is based on specific blood test results called IGF-1 or plasma insulin-like growth factor-1 and the kind of side effects in the person. The therapy helps fix abnormalities related to metabolism, functions, and psychology linked to adult GHD. At the same time, lipolysis or reduction in total body fat, especially in the abdominal region, increases during the replacement therapy. One year of rhGH therapy has been shown to improve the heart from early damage in adult patients with GHD. Evidence suggests that the treatment can boost adult patients' ability to exercise and physical performance.

Omnitrope® (Sandoz, Kundl, Austria) is one of the most effective recombinant human growth hormone (rhGH) therapies used in treating growth hormone deficiency (GHD) in adults. Omnitrope® is produced by genetically modifying an Escherichia coli strain. There is a similarity between Omnitrope® and Genotropin® (Pfizer Limited, Sandwich, UK), while the former was the first to get approval from the European Medicines Agency (EMA) in 2006, which was a significant milestone within the European biosimilar regulatory framework. 

Omnitrope® is approved for use in adult-onset growth hormone deficiency (GHD). Research involving adult patients indicates that the shift from Genotropin® to Omnitrope® does not affect the safety or efficacy. Nevertheless, there is a lack of data on the long-term safety and effectiveness of Omnitrope® for use in everyday clinical settings. The Patients Treated with Omnitrope® (PATRO) Adults study was launched to address this gap, with its beginning seeded in the Omnitrope® Active Pharmacovigilance Program established in agreement with the European Medicines Agency (EMA) following the approval of Omnitrope®. The PATRO Adults study is a comprehensive long-term post-marketing surveillance (PMS) project that evaluated Omnitrope®'s long-term safety and effectiveness in adult patients with GHD. The initiative was taken as a part of the Risk Management Plan for Omnitrope®, which was designed to meet the EMA's requirements. 

The project's Early findings suggest that Omnitrope® can be generally well tolerated in standard clinical practice. Between September 2007 and September 2015, the PATRO Adults study featured 954 patients from eight countries (the Czech Republic, France, Germany, Italy, Spain, Sweden, The Netherlands, and the UK). This report focuses on the results of patients from Italy.

Treatment and Outcomes

Participants in the study were administered Omnitrope® as per the guidelines outlined in the Summary of Product Characteristics and the prescribed information relevant to each country. The main goal of this post-marketing surveillance (PMS) study was to collect and analyze information related to the long-term safety of Omnitrope® when used in a standard clinical setting. In other words, it is essential to understand the comprehensive global safety profile of Omnitrope®. It specifically stresses safety concerns, for example, the potential risk of developing glucose intolerance or diabetes or increased chances of cancer, and its effect on cardiovascular risk factors like blood pressure and levels of inflammatory markers. The results have been segregated and incorporated in the Sandoz Safety Database as Adverse Events (AEs), Adverse Drug Reactions (ADRs), Serious Adverse Events (SAEs), and Serious Adverse Drug Reactions (SADRs).

The next goal of the study was to observe the subjects who had received the treatment and gather data on the effectiveness of the Omnitrope® treatment. Measures like IGF-1 change levels per the normal ranges, depending on age and gender. It was also about understanding the fasting lipid profile and assessing body composition metrics like weight, waist and hip circumference, lean and total body mass, and body mass index.

Contact Us Today For A Free Consultation

Name *

Email *

Phone *

Your Program *

Your State *

Select Age (30+ only) *

* Required

Dear Patient,

Once you have completing the above contact form, for security purposes and confirmation, please confirm your information by calling us.

Please call now: 1-800-380-5339.

Welcoming You To Our Clinic, Professor Tom Henderson.

specialists hgh miami doctors.webp

Related Posts
male doctor examines rack of test tubes in lab

pituitary growth hgh chart hormone.webp

purchase injections hgh chart.webp

Was this article useful to you?

Rate by clicking on a star

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

About Author: Brianna Clark